Analytical Data
-
基因名
SGSH
- Application
-
别名
HSS; MPS3A; SFMD; Sulfamidase; Sulfoglucosamine sulfamidase
-
种属
Human
-
表达系统
E. coli
-
标签
N- His & GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P51688
-
表达区间
Arg21~Asn389
-
分子量
71kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SGSH (sulfoglucosamine sulfohydrolase) is an enzyme that plays a critical role in the catabolism of glycosaminoglycans, specifically heparin and heparan sulfate. Mutations in the SGSH gene are associated with Sanfilippo syndrome type B, a rare neurodegenerative disorder that typically manifests in childhood and leads to progressive cognitive decline and behavioral issues. The study of SGSH recombinant protein is essential for understanding the molecular mechanisms underlying this condition, enabling researchers to investigate the enzyme's structure, function, and interaction with substrates. Additionally, recombinant SGSH protein provides a valuable tool for developing potential therapeutic strategies, including gene therapy and enzyme replacement therapy, aimed at alleviating symptoms and slowing disease progression in affected individuals. By generating and characterizing SGSH in vitro, scientists can explore its enzymatic activity, substrate specificity, and therapeutic potential, thus contributing to a more profound understanding of Sanfilippo syndrome type B and paving the way for innovative treatment approaches.
